Inhibition of PD-L1, via the use of durvalumab, is studied in phase I/II clinical trial, however single use of durvalumab for CCA is not studied yet, in comparison with its utilization as monotherapy in HCC, which presented a moderate improvement for HCC, compared to other ICIs. Here, CD274 is linked to hepatocellular carcinoma.